• Tango Therapeutics to go public with $353m merger deal pharmaceutical-technology
    April 16, 2021
    Tango Therapeutics is set to go public with the signing of a definitive merger agreement with the Boxer Capital-sponsored special purpose acquisition company BCTG Acquisition worth up to a total of approximately $353m.
  • ViiV posts positive long-term data for two-drug HIV regimen Dovato pharmatimes
    October 14, 2020
    GlaxoSmithKline subsidiary ViiV Healthcare has reported new data for its two-drug HIV regimen Dovato, with hopes that the long-term data could encourage clinicians to switch from other triple regimen therapies.
PharmaSources Customer Service